

INDEX

A

ablation (tumor)
 radiofrequency, 139, 141, 157, 159
 thermal, 139, 141, 157, 159

acetaminophen, 2, 9, 86-88, 90, 91, 93

acinus, 31, 35, 36

acute liver failure, 11, 13, 16, 17, 48-51, 62, 87, 92, 101, 104, 106, 114, 119, 130, 133, 134
 Acute Liver Failure Study Group (ALFSG), 51, 92, 134

Agency for Healthcare Research and Quality (AHRQ), 24

AIDS Clinical Trial Group (ACTG), 76

Alagille syndrome, 2, 9, 15, 16, 53, 57, 101, 102, 105, 109

albumin, 45, 120, 131

alcohol/alcoholic liver disease—See fatty liver disease

alpha-1 antitrypsin deficiency, 2, 9, 15, 17, 50, 101, 105, 109, 137, 138

alpha-fetoprotein, 45

aminotransferases (serum), 14, 39, 74, 83, 88, 92, 93

animal models, 6, 21, 33, 35, 40, 41, 43, 46, 47, 50, 51, 57, 58, 63-65, 68, 69, 72, 76, 81-85, 89, 92, 93, 96-99, 103, 105, 106, 115, 116, 122, 133, 138, 139, 143, 146-148, 150, 156, 159

antibody and phage display, 140

anti-cytokine therapy, 80, 82, 83, 85, 122, 126

antioxidants, 75, 80, 81, 91, 93, 142

antiviral therapy
 for hepatitis virus infection, 20, 61-69, 72, 75, 104, 123, 124, 166
 resistance to (nonresponders), 2, 66-69
 antiretroviral therapy (ART) for HIV infection, 19, 71, 72, 74

apoptosis, 40, 45, 89, 112
 anti-apoptotic therapy, 42

artificial/bioartificial liver device, 31, 133, 134

ascites, 6, 11, 20, 129-134

autoimmune hepatitis—See hepatitis, autoimmune

autoimmune liver disease—See hepatitis, autoimmune;
primary biliary cirrhosis, primary sclerosing cholangitis

B

bacterial peritonitis, 6, 129, 131

bariatric surgery, 84, 85
 Longitudinal Assessment of Bariatric Surgery (LABS), 85

benign recurrent intrahepatic cholestasis (BRIC), 55

bile, 52-29, 87, 94-97, 99-102, 104, 110, 115, 144-150, 156

bile canaliculus, 30, 33, 54-56

bile ducts/biliary tract, 1, 6, 10, 11, 15, 19, 31, 45, 46, 52, 53, 57, 87, 94-97, 99-101, 146-150, 153

bile salt/acid, 5, 30-34, 52-59, 146

bile salt export pump (BSEP), 53

biliary atresia, 2, 6, 15-17, 53, 100-106, 119, 145, 167
 Biliary Atresia Research Consortium (BARC), 59, 105
 Kasai procedure (hepatoportoenterostomy), 100-104

biliary ductules—See canals of Hering

biliary pain, 147, 150

bilirubin, 5, 52-59, 120, 145, 147

biomarkers, 42, 43, 49-51, 74, 76, 82, 83, 91, 93, 98, 99, 103-106, 122, 123, 126, 140-143, 147-150, 167

Byler disease—See progressive familial intrahepatic cholestasis

C

canals of Hering, 46

cancer—See hepatocellular carcinoma, cholangiocarcinoma, and hepatoblastoma

carcinogenesis, 5, 6, 45, 46, 48, 51, 104, 136, 138, 139, 141-143

cell/organ culture, 6, 12, 35, 36, 46, 48, 59, 62, 63, 65, 68, 69, 73, 76

cell cycle, 33, 47, 48

cell junctions (gap, tight), 33-36

cell signaling, 33-36, 40, 41, 43-49, 56, 57, 83, 89-91, 102, 111, 112, 122, 140

Center for Scientific Review (CSR), 84, 171, 172

Centers for Disease Control and Prevention (CDC), 12, 13, 17-19, 24, 60, 70, 84, 105, 116

cerebrotendinous xanthomatosis (CTX), 55

chemoembolization (transarterial), 124, 139, 141, 142

chemotherapy, 121, 124, 126, 140, 141

cholangiocarcinoma, 1, 15, 96, 98, 99, 137, 145, 148-150, 153, 165

cholangiocyte, 32, 34-36, 40, 46, 48, 57, 112, 115

cholecystectomy, 14, 20, 146-148, 167

cholecystitis, 145, 147, 148

cholestasis, 2, 15, 52, 53, 59, 95, 96, 100, 101, 103

cholesterol, 31, 33, 34, 50, 52-59, 81, 121, 144-150

chronic liver disease, 1, 2, 5, 6, 9-16, 19, 20, 39, 42, 43, 45, 46, 50, 55, 58, 61-66, 79, 82, 87, 91-93, 101, 102, 105, 110, 112, 113, 116, 119-121, 128-134, 136-140, 148, 155, 156, 166-168

cilia (biliary), 32, 55

cirrhosis, 1, 2, 5, 6, 9, 11, 14-20, 32, 38-42, 45, 46, 48, 53, 55, 58, 61, 63, 75, 79-81, 83, 84, 87, 92, 94-96, 101, 109, 110, 112, 114, 119, 121, 129, 142, 155, 156, 165-167

- cryptogenic, 15-17, 79, 83, 119, 137, 140

clinical trials, 3, 28, 42, 64, 67, 75, 76, 83-85, 88, 91, 92, 103-106, 116, 123-125, 134, 142, 149, 157

collagen, 32, 38-40, 42

computed tomography (CT), 139, 152-154, 156, 159

congenital hepatic fibrosis, 6, 108-110, 112, 115, 116

copper overload—See Wilson disease

covalently closed circular DNA (cccDNA), 65, 67, 69

creatinine, 120

Crigler-Najjar syndrome, 50, 54, 56, 58, 119, 124

cryptosporidiosis, 71

cyclin dependent kinases, 47

cytochrome (CYP), 83, 86, 88

cystic fibrosis, 6, 55, 101, 108-110, 112, 115, 116, 145

cytokines, 33, 34, 41, 44-47, 49, 66, 73, 79, 80, 82, 83, 85, 89, 91, 97, 112, 122, 126

- anti-inflammatory, 97
- pro-inflammatory, 82, 91, 97

cytomegalovirus, 71

cytoskeleton, 33, 34

D

Department of Veterans Affairs (VA), 24, 84, 85, 116

development, 35, 44-51, 59, 103, 106

diabetes, 14, 18, 19, 55, 73, 79, 80, 82, 84, 85, 97, 99, 104, 121, 138

diagnostic criteria, 98, 99, 104-106, 140, 155, 158, 159, 168

differentiation, 32, 33, 45-49, 102, 105

Digestive Diseases Interagency Coordinating Committee (DDICC), 3, 4, 25, 26, 161, 162

- Liver Disease Subcommittee (LDS), 3, 4, 6, 25, 26, 161, 162

disease

- burden, 1-3, 9-19, 26, 28, 62, 72, 91, 93, 102, 103, 106, 110, 138, 167
- grading, 6, 74, 85, 103, 104, 106, 132, 133, 140, 143, 168
- staging, 68, 74, 85, 103-106, 122, 140, 143, 148-150, 153, 168

drug-induced liver disease, 1, 2, 11, 14, 17, 19, 42, 53, 59, 71, 76, 76, 77, 82, 86-93, 101

- Drug-Induced Liver Injury Network (DILIN), 59, 92
- idiosyncratic, 87-90, 92, 93
 - allergic, 87-90, 93
 - non-allergic, 87, 89, 90, 93
- signature, 87, 90, 91, 93

Dubin-Johnson syndrome, 54, 56

E

embryogenesis, 45, 46, 105

end-stage liver disease, 14, 16, 21, 72, 79, 95, 101, 102, 119-121, 165, 166

endoderm, 44, 45, 47, 48, 51

endoplasmic reticulum, 32, 56

endoscopic retrograde cholangiopancreatography (ERCP), 94, 95, 146, 147, 153

endothelial cell, 31, 32, 35, 36, 40, 41, 44-46, 48, 49, 73, 89, 154

enterohepatic circulation (EHC), 52, 53, 145, 147, 150

environmental hepatotoxins, 1, 5, 11, 40, 66, 74, 87, 89, 90, 96, 98, 99, 148

Epstein Barr Virus, 123

esophageal varices, 11, 19, 129, 131-133

extracellular matrix, 32, 35, 40

F

fatigue, 2, 11, 20, 39, 129
 fatty acid, 79-83
 fatty liver disease
 alcoholic, 1, 5, 6, 11, 14, 16, 17, 19, 71, 78-85, 112-113, 116, 119, 137, 140, 166
 nonalcoholic, 1, 2, 5, 6, 11, 14, 42, 71, 73-75, 78-92, 101, 104, 112, 119, 137, 138, 140, 166
 nonalcoholic steatohepatitis, 2, 11, 14, 42, 71, 75, 78-85, 92, 101, 104, 110, 112, 115, 119, 138
 Nonalcoholic Steatohepatitis Clinical Research Network (NASHCRN), 84
 steatosis, 75, 80-83, 85
 fibrogenesis, 32, 42, 137
 fibrosis, 5, 6, 14, 38-43, 48, 49, 51, 53, 74, 76, 77, 79-81, 83, 96, 97, 101, 104, 109, 110, 112, 115, 116, 130, 153, 156, 157, 159, 166, 167
 anti-fibrotic therapy, 85, 104
 Fogarty International Center (FIC), 22, 23, 171
 Food and Drug Administration (FDA), 14, 24, 88, 92, 93, 116, 172, 174

G

gallbladder disease, 1, 2, 6, 9, 11, 14, 19-21, 24, 54, 55, 144-150, 153, 165, 167
 gallstones/cholelithiasis, 1, 2, 6, 11, 14, 19-21, 24, 54, 55, 144-150, 153, 165, 167
 cholesterol gallstones, 55, 144-150
 gallstone pancreatitis, 145
 Helicobacter, 147, 150
 microlithiasis, 147, 150
 nucleation factors, 146, 147, 150
 pigment gallstones, 52, 145, 147
 GB virus C (GBV-C), 75
 gene therapy, 50, 51, 58, 59, 103, 105, 111, 112, 115, 123, 124
 genetic mutations/genetic liver disease, 10, 32, 53-55, 57, 101, 103, 109-116
 genome, genomics, 3, 4, 10, 23, 28, 33, 35, 41, 43, 54, 61, 62, 65, 82, 90, 92, 93, 103, 108, 116, 138, 146, 153, 154
 Gilbert syndrome, 54, 56
 glutathione (GSH), 86, 88
 Golgi apparatus, 32, 33
 graft-versus-host disease, 53
 growth factors, 44-47, 49, 75, 80, 112, 141

H

hemochromatosis (hereditary), 2, 6, 9, 108-116, 137, 138
 hepcidin, 111, 112, 116
 HFE gene, 111-113, 115, 116
 hemophilia, 50, 71, 75
 hepatic encephalopathy, 6, 11, 19, 20, 129, 131-134
 hepatic venous pressure gradient (HVPG), 129, 132
 hepatitis
 autoimmune, 5, 11, 14, 16, 17, 94-99, 101, 119, 165
 drug-induced, 82, 87
 viral, 1, 5, 9, 11-13, 19, 23, 24, 40, 42, 49, 60-69, 71, 72, 76, 82, 89, 95, 101, 104, 130, 138, 168
 hepatitis A, 2, 9, 12, 13, 21, 60-64, 67, 68, 74, 77, 102
 hepatitis B, 6, 12, 13, 16, 17, 19, 21, 24, 39, 60-77, 101, 102, 105, 119, 137-141, 166
 hepatitis B surface antigen (HBsAg), 61-66, 73
 HBV DNA integration and hepatocellular carcinoma, 17, 63, 137, 138
 HBV vaccination, 2, 9, 12, 21, 61-63, 65-69, 74, 102, 139, 166
 hepatitis C, 2, 6, 9, 11-14, 16, 17, 19-21, 24, 60-69, 71-73, 75-77, 112, 113, 116, 119, 121-124, 126, 137, 138, 141, 165, 166, 168
 Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial (HALT-C), 68
 hepatitis C immune globulins (HCIG), 65, 69, 123
 Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C trial (Peds-C), 68
 recurrence, 67, 122-124, 126
 Viral Resistance to Antiviral Therapy of Chronic Hepatitis C trial (Virahep-C), 68
 hepatitis D, 13, 60-62, 64, 67-69
 hepatitis E, 60-62, 64, 68, 69
 woodchuck hepatitis virus, 138, 139
 hepatoblast, 44, 45
 hepatoblastoma, 17, 137
 hepatocarcinogenesis, 5, 6, 45, 46, 48, 51, 104, 136, 138, 139, 141-143
 hepatocellular carcinoma (HCC), 1, 6, 11, 15-17, 24, 63, 81, 92, 110, 119, 121, 124, 135-143, 152, 155, 167
 fibrolamellar, 137
 Milan criteria, 139, 141
 hepatocyte, 30-36, 39, 40, 44-51, 53-59, 61, 65, 73, 79, 80, 103, 105, 111, 124, 136, 138, 139
 hepatoprotective therapy, 42, 58, 91, 93
 hepatopulmonary syndrome, 6, 110, 129, 131-134

hepatorenal syndrome, 6, 129, 131-134
hepatotoxicity, 5, 86-93
herbal medications, 5, 54, 75, 81, 87, 89, 90, 142
 silymarin, 81, 82, 85
 Yin Zhi Huang, 54
hereditary tyrosinemia, 102, 109
highly active antiretroviral therapy (HAART)—See antiviral therapy, for HIV infection
HLA haplotype, 87, 89, 96, 99, 111
Human Genome Project, 3, 4, 10, 28, 33, 54
human immunodeficiency virus-1 (HIV), 2, 5, 19, 24, 67, 70-77, 89, 166
 coinfection (with hepatitis virus and HIV), 24, 67, 70-72, 74, 76
Human Proteome Project, 4, 28, 33
hyperbilirubinemia, 54, 56, 58, 59

I

idiopathic vanishing bile duct syndrome, 53, 87
imaging, 35, 49, 51, 75, 80, 83, 95, 99, 113, 116, 133, 139, 141-143, 146, 148-150, 152-159, 166
 criteria, 155, 156, 158, 159, 168
 functional, 141, 143, 154
 image-guided therapy, 153, 154, 157
 molecular, 148-150, 154, 156, 157, 159
 optical, 156, 159
 paramagnetic polymerized nanoparticles, 154
immune system, 40, 66, 73, 82, 89, 90, 93, 98, 99, 123
 adaptive, 40, 57, 58, 66, 90
 cells of, 32, 41, 46, 49, 66, 70, 79, 82, 94, 96, 97, 99, 111
 innate, 40, 66, 89, 90, 93, 98, 99, 123
immunosuppression/immunosuppressants, 91, 95, 96, 98, 101, 102, 104, 120-123, 126
inflammation, 5, 14, 35, 39-43, 48, 49, 51, 53, 78, 79, 81, 82, 89, 91, 95, 97, 99, 101, 136, 147-150, 156, 159
injury, 1, 2, 5, 11, 14, 19, 20, 23, 32, 37-46, 48, 49, 51, 53-55, 58, 65, 71-76, 78-82, 84-93, 95-99, 101, 103, 109, 112, 113, 115, 116, 122, 124, 130, 136, 156, 165, 166
 drug/toxin-induced—See drug-induced liver disease
 hypoxic injury, 41, 43
 ischemia-reperfusion injury, 41, 43, 124
insulin-sensitizing agents, 75, 80, 85, 141
interdisciplinary, 36, 48, 50, 97, 99, 103, 149
interferon/peginterferon alfa—See antiviral therapy
iron overload—See hemochromatosis

J

Jagged-1, 57, 102
jaundice, 11, 13, 14, 20, 53, 54, 56, 64, 92, 129, 130, 153

K

kernicterus, 56
kidney disease, 6, 11, 19, 64, 67, 69, 110, 112, 116, 129-134, 166
Kupffer cell, 32, 35, 36, 41, 48, 49, 73, 80, 89

L

lactic acidosis, 72, 75
L-carnitine—See nutritional supplements
life cycle (viral), 62-66, 68, 69
lipid, 5, 31, 33, 34, 36, 53-56, 58, 59, 79-81, 83, 85, 102, 146, 147
lipoprotein, 33, 34
lysosome, 32

M

magnetic resonance cholangiopancreatography (MRCP), 153
magnetic resonance imaging (MRI), 83, 139, 153-158
major histocompatibility complex (MHC), 123
metabolic disorders, 1, 11, 17, 40, 50, 51, 101-103, 106, 110, 119, 124-126
metabolome, metabolomics, 74, 76, 81, 83, 85, 90-93, 103, 147, 149, 150, 166
microarray
 gene, 33
 RNA, 154
microtubules, 34
mitochondria, 32, 33, 35, 71, 72, 75-77, 89, 90, 95, 96, 101, 104
 mitochondrial injury, 71, 72, 75, 76, 90
 mitochondrial hepatopathies, 101, 105
Model for End-stage Liver Disease (MELD), 120, 124-126
motors, 33, 34, 55
Mycobacterium avium complex (MAC), 71
myofibroblast, 32, 39

N

N-acetylcysteine (NAC), 85, 87, 91, 133, 134
National Cancer Institute (NCI), 22, 23, 43, 163
National Center for Complementary and Alternative Medicine (NCCAM), 22, 23, 163
National Center for Research Resources (NCRR), 22, 23, 163
National Center on Minority Health and Health Disparities (NCMHD), 22, 23, 163
National Health and Nutrition Examination Survey (NHANES), 105
National Heart, Lung, and Blood Institute (NHLBI), 22, 23, 163
National Human Genome Research Institute (NHGRI), 22, 23, 163
National Institute on Aging (NIA), 22, 23
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 22, 23, 163
National Institute of Allergy and Infectious Diseases (NIAID), 22, 23, 163
National Institute of Child Health and Human Development (NICHD), 22, 23, 85, 163
National Institute of Dental and Craniofacial Research (NIDCR), 22, 23
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 3, 4, 22, 23, 25, 26, 51, 85, 161, 162
 Division of Digestive Diseases and Nutrition (DDDN), 3, 4, 25, 161
 Liver Disease Research Branch (LDRB), 3, 4, 25, 26, 161, 162
National Institute on Drug Abuse (NIDA), 22, 23, 163
National Institute of Environmental Health Sciences (NIEHS), 22, 23, 163
National Institute of Mental Health (NIMH), 22, 23
National Institute of Nursing Research (NINR), 22, 23, 163
necrosis, 40, 46, 79, 86, 90
neonatal cholestatic syndromes, 57, 58, 103, 104, 106, 109, 119
neurological disease, 54, 56, 75, 110, 114, 121, 129, 166
nitrosative stress, 41, 43
nonalcoholic fatty liver disease—See fatty liver disease
nonalcoholic steatohepatitis (NASH)—See fatty liver disease
noninvasive tools—See biomarkers and imaging
nonmammalian model organisms
 Xenopus, 47
 Zebrafish, 47
Notch, 57, 102
nuclear receptors, 54, 55, 88
 orphan, 54, 88

nucleoside analogues, 63, 65, 75, 90, 141
nucleus, 32
nutritional supplements
 L-carnitine, 87
 S-adenosylmethionine, 24, 80, 81, 85, 91
 vitamin E, 81, 83, 85

O

obesity, 14, 55, 79, 80, 82, 84, 89, 104, 138, 145, 149
Office of the Director (OD), 22, 23
 Office of AIDS Research, 163
 Office of Dietary Supplements, 163
 Office of Rare Diseases, 163
 Office of Research on Women's Health, 163
organelle, 32, 33, 35, 43, 55, 89, 90
organogenesis—See development
oval cell, 45-47
overweight, 2, 14, 78, 82, 104
oxidative stress, 41, 43, 80, 82, 89, 50

P

partial hepatectomy, 44-48
Pediatric model for End-stage Liver Disease (PELD), 120, 124-126
peginterferon—See antiviral therapy
peroxisome, 32, 33
phase 1-3 enzymes (drug metabolism), 88
phospholipids, 33, 52, 53, 55, 146
plasma membrane, 32-34, 36, 55
polarity, 30, 33-36
polycystic liver disease, 55, 108-110, 112, 116, 145
porphyria, 6, 50, 108-112, 114-116
 acute intermittent porphyria (AIP), 108, 110, 111
 erythropoietic protoporphyria (EPP), 108, 110, 112
 hereditary coproporphyria (HCP), 108, 110
 porphyria cutanea tarda (PCT), 108, 110, 112
 variegate porphyria (VP), 108, 110
porphyrin, 55, 109, 110, 112, 115
portal hypertension, 1, 6, 11, 20, 39, 110, 127-134, 153, 155, 156
portal vein, 10, 11, 30, 31, 52, 128, 139
positron emission tomography (PET), 154-156, 159
post-transplant lymphoproliferative disease (PTLD), 123, 126

pregnancy (liver diseases in), 53, 55, 57, 59
primary biliary cirrhosis (PBC), 2, 5, 11, 14, 16, 20, 40, 53, 94-99, 119
 antimitochondrial antibodies (AMAs), 95, 96
 antinuclear antibodies (ANAs), 95
primary sclerosing cholangitis (PSC), 5, 11, 14, 16, 54, 94-99, 145, 148, 153
 link to inflammatory bowel disease, 95-97, 99
primordium, 44-47, 51
progenitor cell, 40, 45-49
programmed cell death—See apoptosis
progressive familial intrahepatic cholestasis (PFIC), 53, 55, 59, 101-103, 105
proliferation (cell), 32, 44, 47, 49, 51, 96, 139
proteasome, 32, 35
proteome, proteomics, 4, 28, 33, 35, 36, 41-43, 48, 51, 74, 76, 81, 83, 85, 90-93, 98, 103, 122, 133, 140, 146, 147, 149, 150, 154, 166
prothrombin time, 120
pruritus, 57-59, 129

Q

quality of life, 2, 12, 20, 104, 120, 123, 126, 129, 130, 132, 134, 140-142, 165, 167

R

reactive nitrogen species—See nitrosative stress
reactive oxygen species (ROS)—See oxidative stress
redox state—See oxidative stress
regeneration, 5, 11, 21, 39, 41-51, 91, 112, 118, 122, 126, 132, 134, 156
repair, 5, 39-43, 112
replication
 cell, 44, 45, 47
 viral, 62-69, 124
replicon, 63
ribavirin—See antiviral therapy

S

S-adenosylmethionine (SAM-e)—See nutritional supplements
scarring—See fibrosis
sepsis, 53, 56, 57, 59
septum transversum mesenchyme, 44, 46
shock, 57
silymarin—See herbal medications
sinusoid, 10, 30-32, 39, 40, 43, 56
siRNA, 50, 103, 106
small molecule therapy, 41, 43, 49, 51, 57, 58, 64, 66-69, 103, 105, 106, 131, 134
special populations, 15, 67, 85, 166
 ethnicity/race, 14, 15, 19, 66, 71, 113, 115, 116, 145, 148, 150
 gender, 2, 14, 15, 19, 95, 104, 137, 145
 pediatric, 16, 17, 23, 58, 68, 100-106
sphincter of Oddi, 147, 149, 150
stellate cell, 32, 34-36, 39, 47-49, 73, 89
stem cell, 46, 48-51, 103, 105, 106, 115, 116, 124
surveillance (epidemiologic), 13, 14, 19, 20, 28, 61, 73, 92, 105, 111, 138, 140, 143

T

tissue bank, 6, 142, 143, 155, 159, 161
tissue culture—See cell culture
total parenteral nutrition (TPN)-associated liver disease, 17, 53, 57, 59, 79, 101
training, 2, 23, 36, 93, 149, 158
transcription factors, 45-47, 79, 88
transcriptome, transcriptomics, 90-93
transgenic—See animal models
transjugular intrahepatic portosystemic shunts (TIPS), 131, 153, 155
translation, 3, 4, 21, 28, 33, 36, 39, 40, 42, 43, 51, 57, 65, 72, 92, 99, 110, 147
transplantation, 117-126
 Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL), 51, 68, 125

extended criteria donors, 124
graft tolerance/rejection, 50, 51, 53, 104, 120-126
Immune Tolerance Network (ITN), 125
living donor liver transplantation, 5, 6, 16, 21, 45, 49-51, 102, 118-126, 141, 155, 166
organ donation/waiting list, 102, 119, 120, 124, 125, 129
reduced size liver transplantation, 20, 102, 118
Scientific Registry of Transplant Recipients (SRTR), 15, 16, 125
split liver transplantation, 45, 102, 119
Studies of Pediatric Liver Transplantation (SPLIT), 105, 125
transporters (plasma membrane), 32-34, 36, 54-57, 59, 88, 111, 112
triglyceride, 33, 79, 81, 84

U

UDP-glucuronosyl transferase, 54, 58
ultrasound (US), 83, 142, 153-155
urea cycle disorders, 50
ursodiol, 95-99
 High-Dose Ursodiol Trial, 149

V

vaccine, 2, 9, 12, 21, 61-69, 71, 74, 102, 139, 166
vanishing bile duct syndrome—See idiopathic vanishing bile duct syndrome
veno-occlusive disease, 40
vesicle trafficking, 32, 34, 36

W

wedged hepatic venous pressure (WHVP), 132
Wilson ATPase, 111, 114, 116
Wilson disease, 2, 6, 9, 101, 102, 108-116

X

xenobiotic, 32, 54, 57, 87

Y

Yin Zhi Huang—See herbal medications

Z

zonality, 31, 35